Sardona Therapeutics has built a leading drug discovery platform to identify new small molecules to target RNA-binding proteins (RBP) and modulate RBP-driven biology for the treatment of cancer and other diseases.
↓
RNA dysregulation is a major driver of cancer therapeutic resistance and other disease mechanisms. Aberrant function of RNA-binding proteins leads to RNA dysregulation and loss of normal protein production.
Sardona has built a novel platform to identify new precision medicine small molecule drugs that target RNA-binding proteins and link them to clinically validated genetic alterations.
Sardona’s unique approach has resulted in compounds that inhibit previously undruggable oncogenic drivers and may have applications beyond oncology.
Sardona has built the leading drug discovery platform to target RNA binding proteins (RBPs). The platform’s foundation is our proprietary RBP Topography Map that links different RBPs to specific therapy-resistant cancers. We leverage internally developed screening assays, bioinformatics capabilities and focused small molecule compound libraries to generate best-in-class drug candidates that target individual RBPs. We also believe there are important targets and applications beyond oncology, where Sardona’s platform can identify novel drug leads.
At Sardona Therapeutics, we are blazing a trail for a new way to target clinically established oncogenic pathways driving therapy resistance. With a precision oncology approach, we are advancing our initial programs with the potential to address high unmet needs in various types of genetically defined, metastatic cancer, including breast cancer, non-small cell lung cancer, and colorectal cancer.
By 2030, more than 30 million people in the U.S. will have therapy resistant cancers. We need to act boldly now and explore new approaches. That’s why Sardona Therapeutics is pushing the limits to advance a new class of drugs targeting cancer’s core mechanism and going further to expand the therapeutic options to fight aggressive cancers.
Join Us
